Stefan Kubicka

10.2k total citations · 1 hit paper
159 papers, 6.4k citations indexed

About

Stefan Kubicka is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Stefan Kubicka has authored 159 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 45 papers in Surgery and 39 papers in Molecular Biology. Recurrent topics in Stefan Kubicka's work include Colorectal Cancer Treatments and Studies (40 papers), Gastric Cancer Management and Outcomes (26 papers) and Virus-based gene therapy research (24 papers). Stefan Kubicka is often cited by papers focused on Colorectal Cancer Treatments and Studies (40 papers), Gastric Cancer Management and Outcomes (26 papers) and Virus-based gene therapy research (24 papers). Stefan Kubicka collaborates with scholars based in Germany, United States and France. Stefan Kubicka's co-authors include Michael P. Manns, Christian Trautwein, Lars Zender, Florian Kühnel, Dirk Arnold, Thomas Wirth, Nisar P. Malek, Hans L. Tillmann, K. Lenhard Rudolph and Bettina Mundt and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Stefan Kubicka

150 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

2012 829 citations Richard Greil, Stefan Kubicka et al. profile →

Peers

Countries citing papers authored by Stefan Kubicka

Since Specialization

Citations

This map shows the geographic impact of Stefan Kubicka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Kubicka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Kubicka more than expected).

Fields of papers citing papers by Stefan Kubicka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Kubicka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Kubicka. The network helps show where Stefan Kubicka may publish in the future.

Co-authorship network of co-authors of Stefan Kubicka

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Kubicka. A scholar is included among the top collaborators of Stefan Kubicka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Kubicka. Stefan Kubicka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO 2020 ·Annals of Oncology ·Georg Martin Haag, (unknown), Sylvie Lorenzen, Thomas J. Ettrich, Federico Longo, Alexander Kiani, Marino Venerito, Jörg Trojan, Rolf Mahlberg, Nicolas Moosmann, Benoist Chibaudel, Stefan Kubicka, Richard Greil, S Daum, Michael Geißler, (unknown), Florian Lordick	2
2	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy 2019 ·Nature Communications ·(unknown), Norman Woller, Jennifer D. Brooks, Bettina Fleischmann-Mundt, Nikolas T. Martin, Arnold Kloos, Sarah Knocke, (unknown), Michael P. Manns, Stefan Kubicka, Thomas Wirth, Rita Gerardy‐Schahn, Florian Kühnel	52
3	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer 2017 ·Cancer Research ·Jennifer D. Brooks, Bettina Fleischmann-Mundt, Norman Woller, (unknown), Silvia Ribback, (unknown), İhsan Ekin Demir, (unknown), Güralp O. Ceyhan, Michael P. Manns, Thomas Wirth, Stefan Kubicka, Günter Bernhardt, Mark J. Smyth, Diego F. Calvisi, Engin Gürlevik, Florian Kühnel	55
4	Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials 2016 ·Gastroenterology Research and Practice ·Ralf‐Dieter Hofheinz, Ulrich Ronellenfitsch, Stefan Kubicka, Alfredo Falcone, Iris Burkholder, Ulrich Hacker	9
5	Biliary Tract Cancer: A Survey Regarding the Current Oncological Daily Care Practice in Germany 2012 ·Onkologie ·Marianne Sinn, Sven Bischoff, Oliver Nehls, Uwe Pelzer, Fritz von Weizsäcker, Stefan Kubicka, Jens Stieler, Karel Caca, Hanno Riess	1
6	Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography—A prospective study 2011 ·Digestive and Liver Disease ·B Boozari, B. Soudah, Kinan Rifai, (unknown), Arndt Vogel, Hartmut Hecker, Andreas Hahn, Jérôme Schlué, Christoph F. Dietrich, Mathias Bähr, Stefan Kubicka, Michael P. Manns, M Gebel	63
7	Endocavitary Contrast Enhanced Ultrasound (CEUS) – Work in Progress 2011 ·Ultraschall in der Medizin - European Journal of Ultrasound ·(unknown), (unknown), (unknown), Benjamin Braun, Stefan Kubicka, Wolfgang Blank	26
8	Evaluation of Sound Speed for Detection of Liver Fibrosis 2010 ·Journal of Ultrasound in Medicine ·B Boozari, Andrej Potthoff, Ingmar Mederacke, Andreas Hahn, Ansgar Reising, Kinan Rifai, Heiner Wedemeyer, Mathias Bähr, Stefan Kubicka, Michael P. Manns, M Gebel	32
9	Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity 2010 ·Molecular Therapy ·Engin Gürlevik, Norman Woller, (unknown), (unknown), Arnold Kloos, Michael P. Manns, Lars Zender, Florian Kühnel, Stefan Kubicka	22
10	VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1 2009 ·Gene Therapy ·(unknown), Engin Gürlevik, (unknown), Norman Woller, Nisar P. Malek, Lars Zender, Michael P. Manns, Thomas Wirth, Florian Kühnel, Stefan Kubicka	23
11	The challenges in primary sclerosing cholangitis – Aetiopathogenesis, autoimmunity, management and malignancy 2008 ·Journal of Hepatology ·Tobias J. Weismüller, Jochen Wedemeyer, Stefan Kubicka, Christian P. Strassburg, Michael P. Manns	119
12	Adjuvante Therapie des Kolonkarzinoms 2008 ·Onkologie ·Tanja Trarbach, Stefan Kubicka, Ulrich Hacker, Karsten Ridwelski, Anke Reinacher‐Schick	4
13	Testing the importance of p27 degradation by the SCF ^skp2 pathway in murine models of lung and colon cancer 2006 ·Proceedings of the National Academy of Sciences ·(unknown), Carrie M. Garrett-Engele, Uta Kossatz-Boehlert, Xueyan Chen, Eduardo Firpo, Viktor Grünwald, Kenji Kamino, Ludwig Wilkens, Ulrich Lehmann, Jan Buer, Robert Geffers, Stefan Kubicka, Michael P. Manns, Peggy L. Porter, James M. Roberts, Nisar P. Malek	60
14	Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways 2003 ·Cancer Gene Therapy ·Florian Kühnel, Lars Zender, Thomas Wirth, Bernd Schulte, Christian Trautwein, Michael P. Manns, Stefan Kubicka	3
15	VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo 2002 ·Cancer Gene Therapy ·Lars Zender, Florian Kühnel, (unknown), Michael P. Manns, Stefan Kubicka	34
16	Low frequency of HLA-DRB111 in hepatitis C virus induced end stage liver disease 2001 ·Gut* ·Hans L. Tillmann, (unknown), Christian Trautwein, Volker Kliem, (unknown), (unknown), Klaus H.W. Böker, Stefan Kubicka, (unknown), W Stangel, Michael P. Manns	53
17	Dissection of the Intracellular Pathways in Hepatocytes Suggests a Role for Jun Kinase and IFN Regulatory Factor-1 in Con A-Induced Liver Failure 2001 ·The Journal of Immunology ·Konrad L. Streetz, (unknown), (unknown), (unknown), Stefan Kubicka, Gabriele Sass, Stephan C. Bischoff, Michael P. Manns, Gisa Tiegs, Christian Trautwein	51
18	Das Gallenblasen und Gallengangskarzinom 2000 ·Der Internist ·Stefan Kubicka, Michael P. Manns	2
19	Molecular Mechanisms of TNF Receptor-Mediated Signaling 1998 ·Recent results in cancer research ·Nisar P. Malek, (unknown), Stefan Kubicka, Michael P. Manns, Christian Trautwein	14
20	Clinical relevance of mutations in the precore genome of the hepatitis B virus. 1995 ·Gut ·Hans L. Tillmann, Christian Trautwein, Diana L. Walker, Kojiro Michitaka, Stefan Kubicka, Klaus H.W. Böker, Michael P. Manns	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact